In patients with biochemical recurrence of prostate cancer, 68Ga-PSMA has shown higher sensitivity in bone and soft tissue disease with greater lesion conspicuity, particularly in bone [12, 43]. This evidence concerns the gene FOLH1 and prostate carcinoma.